Two-year-old Bain Brandon has Type 1 diabetes and needs insulin to live. But even with health insurance, the price tag isn’t ...

A monthly out-of-pocket cap on insulin for Medicare beneficiaries with type 2 diabetes is linked to some clinical benefits as ...

The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults with type 2 diabetes, developer Novo Nordisk announced. Of note, the agency ...

Advocates expect the young adult population to especially benefit from the bill, since many struggle to get high-quality ...

Read more from STAT contributor Brianna Abbott on the popular vote winner. And STAT’s Amanda Erickson, who edits this very newsletter, has a dispatch on the research our editors chose as the best ...

Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.

Insulin resistance occurs when your body’s cells become less responsive to insulin, the hormone responsible for moving s ...

A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...

*A gene therapy that may eliminate, or significantly reduce, the need for daily insulin injections is preparing to enter ...

Metabolic dysfunction may be more than a comorbidity in bipolar disorder—it could be a key driver of disease progression and treatment outcomes.

The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal ...